Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

By sjmartinez • May 15, 2024

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman G, Caskey M, Hughes MD, Smith DM, Eron JJ; ACTIV-2/A5401 Study Team. Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial. Pathog Immun. 2024 May 6;9(1):138-155. doi: 10.20411/pai.v9i1.660. PMID: 38746756; PMCID: PMC11093219.

Tags: covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, outpatient treatment, Publications, SARS-CoV-2, subcutaneous

Heterozygous NTHL1 variant in a breast cancer survivor with malignant pleural effusion revealing metastatic colon adenocarcinoma

Lewis LK, Varda MM, McCann KE, Huang C. Heterozygous NTHL1 variant in a breast cancer survivor with malignant pleural effusion revealing metastatic colon adenocarcinoma. BMJ[...]

CTA-Derived Plaque Characteristics and Risk of Acute Coronary Syndrome in Patients With Coronary Artery Calcium Score of Zero: Insights From the ICONIC Trial

Jonas RA, Nurmohamed NS, Crabtree TR, Aquino M, Jennings R, Choi AD, Lin FY, Lee SE, Andreini D, Bax J, Cademartiri F, Chinnaiyan K, Chow[...]

The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

Golub LS, Manubolu VS, Aldana-Bitar J, Dahal S, Verghese D, Alalawi L, Krishnan S, Kianoush S, Benzing T, Ichikawa K, Kinninger A, Fazlalizadeh H, Pourafkari[...]